209 related articles for article (PubMed ID: 19828375)
1. How does inflammation cause Barrett's metaplasia?
Colleypriest BJ; Ward SG; Tosh D
Curr Opin Pharmacol; 2009 Dec; 9(6):721-6. PubMed ID: 19828375
[TBL] [Abstract][Full Text] [Related]
2. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
3. Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia.
Souza RF
J Gastroenterol; 2017 Jul; 52(7):767-776. PubMed ID: 28451845
[TBL] [Abstract][Full Text] [Related]
4. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
[TBL] [Abstract][Full Text] [Related]
5. Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
Shivappa N; Hebert JR; Anderson LA; Shrubsole MJ; Murray LJ; Getty LB; Coleman HG
Br J Nutr; 2017 May; 117(9):1323-1331. PubMed ID: 28571591
[TBL] [Abstract][Full Text] [Related]
6. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
7. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein in human oesophagus, Barrett's epithelium and adenocarcinoma.
Coyle P; Mathew G; Game PA; Myers JC; Philcox JC; Rofe AM; Jamieson GG
Br J Cancer; 2002 Aug; 87(5):533-6. PubMed ID: 12189552
[TBL] [Abstract][Full Text] [Related]
9. Acid reflux and oesophageal cancer.
Nicholson A; Jankowski J
Recent Results Cancer Res; 2011; 185():65-82. PubMed ID: 21822820
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology of Barrett's cancer.
Atherfold PA; Jankowski JA
Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
[TBL] [Abstract][Full Text] [Related]
11. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
12. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assessment of Survivin and Bcl3 expression as potential biomarkers for NF-κB activation in the Barrett metaplasia-dysplasia-adenocarcinoma sequence.
Puccio I; Khan S; Butt A; Graham D; Sehgal V; Patel D; Novelli M; Lovat LB; Rodriguez-Justo M; Hamoudi RA
Int J Exp Pathol; 2018 Feb; 99(1):10-14. PubMed ID: 29473241
[TBL] [Abstract][Full Text] [Related]
14. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
15. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?
Fitzgerald RC
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i21-6. PubMed ID: 15711004
[TBL] [Abstract][Full Text] [Related]
16. Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction.
Sharma P
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():48-54; discussion 61-2. PubMed ID: 15456464
[TBL] [Abstract][Full Text] [Related]
17. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
18. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
19. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma.
Song S; Guha S; Liu K; Buttar NS; Bresalier RS
Gut; 2007 Nov; 56(11):1512-21. PubMed ID: 17604323
[TBL] [Abstract][Full Text] [Related]
20. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]